Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL363373 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL840939 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL14304968 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL12000798 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL5452846 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL295573 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL23845860 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL723342 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL13460643 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL13460354 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 731 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367192-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LTD (NZ) | 2025-12-04 | — | — | US | claimed |
| US-12472177-B2 | Bicyclic compounds and methods for their use in treating Pitt Hopkins syndrome | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2025-11-18 | — | — | US | claimed |
| EP-4583860-A1 | INHIBITORS OF THE CERAMIDE METABOLIC PATHWAY FOR OVERCOMING IMMUNOTHERAPY RESISTANCE IN CANCER | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-07-16 | — | — | EP | claimed |
| WO-2024163538-A2 | MODULATION OF LYSOSOMAL PHOSPHOLIPASE A2 FOR TREATMENT OF BIS (MONOACYLGLYCERO)PHOSPHATE-RELATED DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-08-08 | — | — | WO | claimed |
| EP-4384220-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | The Johns Hopkins University (US) | 2024-06-19 | — | — | EP | claimed |
| CN-118139642-A | Compositions and methods for treating cancer | 约翰·霍普金斯大学 | 2024-06-04 | — | — | CN | claimed |
| WO-2024052356-A1 | INHIBITORS OF THE CERAMIDE METABOLIC PATHWAY FOR OVERCOMING IMMUNOTHERAPY RESISTANCE IN CANCER | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-03-14 | — | — | WO | claimed |
| CN-115161289-B | Recombinant adeno-associated virus for treating inflammatory diseases, construction method and application thereof | 东南大学 | 2023-12-05 | — | — | CN | claimed |
| US-20230301994-A9 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2023-09-28 | — | — | US | claimed |
| WO-2023174265-A1 | RECOMBINANT ADENO-ASSOCIATED VIRUS FOR TREATING INFLAMMATORY DISEASES, AND CONSTRUCTION METHOD THEREFOR AND USE THEREOF | 东南大学 | 2023-09-21 | — | — | WO | claimed |
| EP-0720852-B1 | REMEDY FOR NERVOUS DISEASES | SEIKAGAKU KOGYO CO LTD (JP) | 2000-11-22 | — | — | EP | claimed |
| WO-2000062780-A1 | USE OF GLUCOSYLCERAMIDE SYNTHESIS INHIBITORS IN THERAPY | OXFORD GLYCOSCIENCES (UK) LIMITED (GB) | 2000-10-26 | — | — | WO | claimed |
| WO-2000062779-A1 | COMBINATION OF GLUCOSYLCERAMIDE SYNTHESIS INHIBITORS AND GLYCOLIPID DEGRADING ENZYME IN THERAPY | OXFORD GLYCOSCIENCES (UK) LIMITED (GB) | 2000-10-26 | — | — | WO | claimed |
| EP-0996433-A1 | METHODS FOR TREATMENT OF CONDITIONS ASSOCIATED WITH LACTOSYLCERAMIDE | THE JOHNS HOPKINS UNIVERSITY (US) | 2000-05-03 | — | — | EP | claimed |
| WO-2000006145-A1 | METHODS FOR TREATING CONDITIONS MODULATED BY LACTOSYLCERAMIDE | JOHNS HOPKINS UNIVERSITY (US) | 2000-02-10 | — | — | WO | claimed |
| US-5976781-A | DIAGNOSING MALARIA BY MIXING BLOOD WITH ENZYME INHIBITOR, DETERMINING ENZYME ACTIVITY, COMPARING TO CONTROL SAMPLE; PLASMODIUM ENZYME IS MORE SENSITIVE TO INHIBITION SO DEACTIVATION INDICATES DISEASE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1999-11-02 | — | — | US | claimed |
| US-5849326-A | Method for treating neuronal diseases via administration of 2-acylaminopropanol derivatives | SEIKAGAKU CORPORATION (JP) | 1998-12-15 | — | — | US | claimed |
| US-5707649-A | USING A 2-ACYLAMINOPROPANOL DERIVATIVE | SEIKAGAKU CORPORATION (JP) | 1998-01-13 | — | — | US | claimed |
| EP-0720852-A1 | REMEDY FOR NERVOUS DISEASES | SEIKAGAKU CORPORATION (JP) | 1996-07-10 | — | — | EP | claimed |
| US-5041441-A | Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1991-08-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367192-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | QPCT, GRIA2, GGPS1 | UGCG 54/4885KMT2A 500/4885MEN1 1673/4885 |
| US-20230301994-A9 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | QPCT, GRIA2, GGPS1 | UGCG 54/4885KMT2A 500/4885MEN1 1673/4885 |
| US-12472177-B2 | Bicyclic compounds and methods for their use in treating Pitt Hopkins syndrome | QPCT, GRIA2, GGPS1 | UGCG 54/4885KMT2A 500/4885MEN1 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.